ObsEva SA Announces Dismissal Of Moratorium Proceedings By Court In Geneva

(RTTNews) - ObsEva SA (OBSV) reported that the competent court in Geneva, Switzerland has granted the company's request to withdraw its moratorium considering that the company is no longer over-indebted. The company resolved its over-indebtedness due to the sale of all its rights to Ebopiprant to XOMA (XOMA).

Brian O'Callaghan, CEO of ObsEva, said: "Having resolved our over-indebtedness and strengthened our financial position with a suite of restructuring initiatives in recent months, we are now focusing our resources on nolasiban."

ObsEva retains worldwide, exclusive, commercial rights for nolasiban, except for the People's Republic of China.

For More Such Health News, visit rttnews.com.